Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Peptidylprolyl isomerase A pseudogene 54 (PPIAP54) is annotated as a *pseudogene* in the human genome, meaning it is a genomic sequence similar to the functional gene Peptidylprolyl isomerase A (PPIA) but is presumed nonfunctional due to mutations or lack of coding potential. Pseudogenes can play regulatory roles in rare cases (for instance, as competitive endogenous RNAs), but there is no evidence in the literature or gene databases to support any coding or direct regulatory function for PPIAP54. As a member of a large family of human pseudogenes, its main value is as a genomic reference to its parental gene, not as a therapeutic or diagnostic target. The parental gene, PPIA (cyclophilin A), is an enzyme involved in protein folding and multiple cellular processes, with roles in inflammation and various diseases, but PPIAP54 does not encode this protein and has no implicated role in disease pathogenesis. There are no known drugs, mechanisms of action, or established biomarkers involving PPIAP54.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Peptidylprolyl isomerase A pseudogene 54 (PPIAP54).